Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers.
about
Ketamine: 50 Years of Modulating the MindOral Ketamine in Treatment-Resistant Depression: A Clinical Effectiveness Case SeriesKetamine for chronic pain: risks and benefits.Intranasal naltrexone and atipamezole for reversal of white-tailed deer immobilized with carfentanil and medetomidine.A parallel chiral-achiral liquid chromatographic method for the determination of the stereoisomers of ketamine and ketamine metabolites in the plasma and urine of patients with complex regional pain syndrome.Pharmacodynamic profiles of ketamine (R)- and (S)- with 5-day inpatient infusion for the treatment of complex regional pain syndrome.A randomized controlled trial of intranasal ketamine in major depressive disorder.New targets for rapid antidepressant action.Oral ketamine in the palliative care setting: a review of the literature and case report of a patient with neurofibromatosis type 1 and glomus tumor-associated complex regional pain syndromeThe analgesic effect of combined treatment with intranasal S-ketamine and intranasal midazolam compared with morphine patient-controlled analgesia in spinal surgery patients: a pilot study.CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects.Intranasal sufentanil/midazolam versus ketamine/midazolam for analgesia/sedation in the pediatric population prior to undergoing multiple dental extractions under general anesthesia: a prospective, double-blind, randomized comparison.Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart reviewIntranasal ketamine for acute traumatic pain in the Emergency Department: a prospective, randomized clinical trial of efficacy and safety.Enantioselective pharmacokinetics of (R)- and (S)-ketamine after a 5-day infusion in patients with complex regional pain syndrome.Effect of rifampicin on S-ketamine and S-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administrationSimultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression.Study protocol of a randomised controlled trial of intranasal ketamine compared with intranasal fentanyl for analgesia in children with suspected, isolated extremity fractures in the paediatric emergency department.Use of human microsomes and deuterated substrates: an alternative approach for the identification of novel metabolites of ketamine by mass spectrometry.Ketamine for the treatment of chronic non-cancer pain.Advances in translational neuropathic research: example of enantioselective pharmacokinetic-pharmacodynamic modeling of ketamine-induced pain relief in complex regional pain syndrome.Regioselective biotransformation of CNS drugs and its clinical impact on adverse drug reactions.Pharmacokinetic and pharmacodynamic considerations for NMDA receptor antagonists in the treatment of chronic neuropathic pain.Ketamine: use in anesthesia.Ketamine as a new treatment for depression: a review of its efficacy and adverse effects.The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders.Subdissociative intranasal ketamine plus standard pain therapy versus standard pain therapy in the treatment of paediatric sickle cell disease vaso-occlusive crises in resource-limited settings: study protocol for a randomised controlled trialKetamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy.Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing.The absolute bioavailability of racemic ketamine from a novel sublingual formulation.Comparing the analgesic effect of intranasal with intravenous ketamine in isolated orthopedic trauma: A randomized clinical trialOral Ketamine for Acute Pain Management After Amputation Surgery.Recent development in therapeutics for breakthrough pain.Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders.Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine.Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain.Exploring the pharmacokinetics of oral ketamine in children undergoing burns procedures.Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression.Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study.Intranasal ketamine for analgesia in the emergency department: a prospective observational series.
P2860
Q28077524-D40A63CC-B401-4F74-9E38-EF1445306035Q30491706-1ED91D5F-7E39-4E58-91BE-58932A68993BQ33582045-C4B0F189-3F0D-4E38-8225-F314372A5025Q33801355-770D16C2-ACA7-4127-B804-BB8F7D49307FQ34166221-6BC33048-26B2-4291-85DB-D2E8C2D2F1B2Q34179516-BD3D4313-EB93-4A09-8D25-24176D9EC79EQ34288196-F2BC7D18-0A7E-4244-91C0-22D4528DD482Q34507177-871FD5BC-36D7-4B88-B7C4-0E4FF5C3CF0DQ34554563-1A0CBC38-8B58-4F37-806C-811E3C64FF9AQ35101015-C46D2395-6405-4177-B907-95583B25AC94Q35972237-64FF1284-6C42-4F47-A3BF-BA315C6314B4Q36035429-87C5C017-65DA-4F32-A148-1EB4C231791DQ36176755-E66091A1-E7AD-4775-B1F0-D56C4CC386FEQ36187742-89F3FF3F-462E-485B-93DE-15DF551BFE20Q36430033-BF87211E-CA2A-4D45-AD6F-7CD58EFA710DQ36578014-D5DEF3D4-44D5-4F8F-8B55-1CE1BFE70043Q36779133-9D94823C-306B-4923-B5CA-FAAF6F22A7CDQ37252091-3C07757F-28D1-43C2-B1C9-21D0FE775F49Q37266290-F773532B-482E-40F1-8493-3E569FBD212FQ37786623-57029D18-C466-42B3-852B-218BEE1DA73CQ37848196-5BBDEBE3-5431-449B-9A6B-99D8EB6E5DB1Q38008438-808BB47A-7B68-44DF-8CEC-9171D6CA31EDQ38032607-03376DD2-26F1-447D-8222-88EEB38EC032Q38092243-7AAA01A5-12B5-497B-ABE0-902D657916FFQ38105535-9714D299-4A56-4922-8AF0-C11CEFB08BA8Q38629117-AC83B6FD-C540-451C-B3FA-76607929A560Q38683376-7012D837-1462-4B9B-B397-9864E967B48CQ38793772-49615B5A-1D6C-4F8C-A5AD-9C9F27EB977DQ41338181-57BE87CF-C07E-4851-A40A-7E0E135A1BB6Q42283150-E17D348F-99B8-45A4-ABAB-BAE827BD353FQ42362224-1D89916F-241B-4047-B85C-5406F223FF96Q43075818-93602FE4-9DFC-4745-B876-F25B4373A6B9Q43085276-65439098-172B-4C48-BB52-6451F85DD38CQ43086364-FD08D4A0-A6CB-4F4B-B8A2-32154D890A05Q43246296-D02C6F42-DF36-435A-9A44-A61FAC98CAF4Q43280523-DA04980D-6622-42B2-960F-6DD80800A60CQ44201200-A5F75743-2D65-42B4-BE11-0AEC7231A93BQ44647972-2A920EE5-5028-4525-BFFF-99FE3567F5B7Q47549625-2CBB2A45-4B57-4B59-83A2-34545950D3ADQ47961019-24502219-E0A6-4971-869F-58BEA62C4EF5
P2860
Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Plasma concentration profiles ...... o healthy Japanese volunteers.
@en
Plasma concentration profiles ...... o healthy Japanese volunteers.
@nl
type
label
Plasma concentration profiles ...... o healthy Japanese volunteers.
@en
Plasma concentration profiles ...... o healthy Japanese volunteers.
@nl
prefLabel
Plasma concentration profiles ...... o healthy Japanese volunteers.
@en
Plasma concentration profiles ...... o healthy Japanese volunteers.
@nl
P2093
P2860
P356
P1476
Plasma concentration profiles ...... o healthy Japanese volunteers.
@en
P2093
Katsuyoshi Uchino
Michiteru Ohtani
Naofumi Ashizawa
Satoru Kariya
Takao Aoyama
Tatsuji Iga
Teiko Hiraishi
Yasuhiko Yamada
Yoshikazu Yamamura
Yoshitsugu Yanagihara
P2860
P356
10.1002/BDD.336
P577
2003-01-01T00:00:00Z